These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 21284830)
21. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure. Park H; Chi O; Kim J; Hong S J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333 [TBL] [Abstract][Full Text] [Related]
22. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Sakkiah S; Thangapandian S; John S; Lee KW Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051 [TBL] [Abstract][Full Text] [Related]
23. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas. Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905 [TBL] [Abstract][Full Text] [Related]
24. High level expression, activation, and antagonism of CC chemokine receptors CCR2 and CCR3 in Chinese hamster ovary cells. Parody TR; Stone MJ Cytokine; 2004 Jul; 27(1):38-46. PubMed ID: 15207250 [TBL] [Abstract][Full Text] [Related]
25. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of alpha-glucosidase inhibitors. Bharatham K; Bharatham N; Park KH; Lee KW J Mol Graph Model; 2008 Jun; 26(8):1202-12. PubMed ID: 18096420 [TBL] [Abstract][Full Text] [Related]
26. Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/eotaxin-1. Millard CJ; Ludeman JP; Canals M; Bridgford JL; Hinds MG; Clayton DJ; Christopoulos A; Payne RJ; Stone MJ Structure; 2014 Nov; 22(11):1571-81. PubMed ID: 25450766 [TBL] [Abstract][Full Text] [Related]
27. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. Evers A; Klabunde T J Med Chem; 2005 Feb; 48(4):1088-97. PubMed ID: 15715476 [TBL] [Abstract][Full Text] [Related]
28. On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches. Huang D; Gu Q; Ge H; Ye J; Salam NK; Hagler A; Chen H; Xu J J Chem Inf Model; 2012 May; 52(5):1356-66. PubMed ID: 22545675 [TBL] [Abstract][Full Text] [Related]
30. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding. Patny A; Desai PV; Avery MA Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041 [TBL] [Abstract][Full Text] [Related]
31. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. Lorenzi S; Mor M; Bordi F; Rivara S; Rivara M; Morini G; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV Bioorg Med Chem; 2005 Oct; 13(19):5647-57. PubMed ID: 16085419 [TBL] [Abstract][Full Text] [Related]
32. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Edwards BS; Bologa C; Young SM; Balakin KV; Prossnitz ER; Savchuck NP; Sklar LA; Oprea TI Mol Pharmacol; 2005 Nov; 68(5):1301-10. PubMed ID: 16118363 [TBL] [Abstract][Full Text] [Related]
33. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors. Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114 [TBL] [Abstract][Full Text] [Related]
34. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies. Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816 [TBL] [Abstract][Full Text] [Related]
35. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist. Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555 [TBL] [Abstract][Full Text] [Related]
36. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. Evers A; Hessler G; Matter H; Klabunde T J Med Chem; 2005 Aug; 48(17):5448-65. PubMed ID: 16107144 [TBL] [Abstract][Full Text] [Related]
37. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques. Wei HY; Tsai KC; Lin TH J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911 [TBL] [Abstract][Full Text] [Related]
38. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. López-Rodríguez ML; Benhamú B; de la Fuente T; Sanz A; Pardo L; Campillo M J Med Chem; 2005 Jun; 48(13):4216-9. PubMed ID: 15974573 [TBL] [Abstract][Full Text] [Related]
39. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists. Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422 [TBL] [Abstract][Full Text] [Related]
40. The first pharmacophore model for potent G protein-coupled receptor 119 agonist. Zhu X; Huang D; Lan X; Tang C; Zhu Y; Han J; Huang W; Qian H Eur J Med Chem; 2011 Jul; 46(7):2901-7. PubMed ID: 21524831 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]